Menopausal hormone therapy and risk of cholecystectomy: A prospective study based on the French E3N cohort

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 7, 2013, Pages 555-561

  Racine, Antoine ^a,b   Bijon, Anne ^a   Fournier, Agnès ^a   Mesrine, Sylvie ^a   Clavel Chapelon, Françoise ^a   Carbonnel, Franck ^a,b   Boutron Ruault, Marie Christine ^a  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; NORPREGNANE DERIVATIVE; PREGNANE DERIVATIVE; PROGESTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLECYSTECTOMY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRANCE; GALLBLADDER DISEASE; HORMONAL THERAPY; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MENOPAUSE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 84876883103     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121490     Document Type: Article

References (31)

1. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006;368:230-9.
2. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology 2011;140:508-16.
3. Heaton KW, Braddon FE, Mountford RA, et al. Symptomatic and silent gall stones in the community. Gut 1991;32:316-20.
4. Tsai C-J, Leitzmann MF, Willett WC, et al. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut 2006;55:708-14.
5. Tsai C-J, Leitzmann MF, Willett WC, et al. Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women. Gastroenterology 2005;129:105-12.
6. Boland LL, Folsom AR, Rosamond WD. Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study. Ann Epidemiol 2002;12:131-40.
7. Niemi M, Kervinen K, Rantala A, et al. The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects. Gut 1999;44:557-62.
8. Everhart JE, Khare M, Hill M, et al. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999;117:632-9.
9. Liu B, Beral V, Balkwill A, et al.; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008;337:a386.
10. Mamdani MM, Tu K, van Walraven C, et al. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ 2000;162:1421-4.
11. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
12. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005;293:330-9.
13. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001;135:493-501.
14. Farquhar C, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009; (2): CD004143.
15. Clavel-Chapelon F, van Liere MJ, Giubout C, et al. E3N, a French cohort study on cancer risk factors. E3N Group. Etude Epidémiologique auprès de femmes de l'Education Nationale. Eur J Cancer Prev 1997;6:473-8.
16. Riboli E. Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol 1992;3:783-91.
17. Fournier A, Mesrine S, Boutron-Ruault MC, et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138-43.
18. van Liere MJ, Lucas F, Clavel F, et al. Relative validity and reproducibility of a French dietary history questionnaire. Int J Epidemiol 1997;26(Suppl 1):S128-36.
19. Lucas F, Niravong M, Villeminot S, et al. Estimation of food portion size using photographs: validity, strengths, weaknesses and recommendations. J Hum Nutr Diet 1995;8:65-74.
20. Kmetic A, Joseph L, Berger C, et al. Multiple imputation to account for missing data in a survey: estimating the prevalence of osteoporosis. Epidemiology 2002;13:437-44.
21. Friedrich N, Völzke H, Hampe J, et al. Known risk factors do not explain disparities in gallstone prevalence between Denmark and northeast Germany. Am J Gastroenterol 2009;104:89-95.
22. Wang HH, Portincasa P, Wang DQ-H. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci 2008;13:401-23.
23. Buch S, Schafmayer C, Völzke H, et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 2010;139(6):1942-51.e2.
24. Wang HH, Liu M, Clegg DJ, et al. New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta 2009;1791:1037-47.
25. Uhler ML, Marks JW, Judd HL. Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 2000;7:162-7.
26. Dhiman RK, Sarkar PK, Sharma A, et al. Alterations in gallbladder emptying and bile retention in the absence of changes in bile lithogenicity in postmenopausal women on hormone replacement therapy. Dig Dis Sci 2004;49:1335-41.
27. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991;100:482-8.
28. Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260-8.
29. de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort. Diabetologia 2009;52:2092-100.
30. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-5.
31. Romieu I, Fabre A, Fournier A, et al. Postmenopausal hormone therapy and asthma onset in the E3N cohort. Thorax 2010;65:292-7.